Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

NCT03154385 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Rituximab (Mabthera ®) Belimumab (Benlysta ®)

Sponsor

Assistance Publique - Hôpitaux de Paris